Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies

Abstract:
MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Midatech Group Ltd, a world leader in the production and application of synthetically produced nanoparticles, announced today a partnership to develop new drug formulations combining biocompatible nanocells and PharmFilm delivery technologies.

MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies

WARREN, NJ and OXFORDSHIRE, England | Posted on November 3rd, 2008

Under terms of the agreement, MonoSol Rx and Midatech will jointly research, develop and commercialize new drug candidates designed to deliver therapeutic nanoparticles in thin film. Research and development will occur at MonoSol Rx's facility in Portage, Indiana and Midatech's facilities in Spain and Switzerland. Further terms were not disclosed.

A. Mark Schobel, president and CEO of MonoSol Rx, stated, "Our collaboration with Midatech provides us with an exciting entry into the emerging field of nanomedicine. The size and chemical composition of Midatech's biocompatible nanocells are ideally suited for delivery using our PharmFilm technology, and should provide another avenue for us to extend the commercial potential of new and currently marketed drugs. The combination of these two complementary and well-matched technologies offers a unique opportunity to move beyond the limitations of traditional delivery formulations to create new and compelling drug candidates with the potential for greater convenience, efficacy at lower doses, and faster onset of action. Most importantly, the mating of MonoSol Rx's and Midatech's technologies will enable the oral delivery of many challenging drugs that up to now could not be delivered orally."

Midatech's biocompatible nanocells possess a number of unique properties ideal for therapeutics, diagnostics and other enabling applications. Among the attributes, Midatech's nanocells are water soluble; can present multiple ligands, allowing for multivalent drug or multi-drug delivery on a single particle; and can be delivered via different routes of administration due to their size and stability to enzymatic digestion.

Professor Tom Rademacher, Chairman of Midatech Group, commented, "MonoSol Rx's PharmFilm technology provides an ideal platform for us to evaluate clinical applications for our biocompatible nanocell technology. PharmFilm's ability to carry highly uniform, accurate doses makes it well-suited to deliver our biocompatible nanocells sublingually, buccally or through traditional intragastric delivery. We look forward to working with MonoSol Rx to develop products with new methods of administration for existing drugs."

Keith J. Kendall, executive vice president and CFO of MonoSol Rx, stated, "Midatech's decision to partner with us is a testament to the strength and versatility of our PharmFilm technology platform. As partners, both MonoSol Rx and Midatech are well-positioned to develop and introduce the first thin film nanomedicines into the market."

####

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of currently marketed drugs. The Company is a leader in thin film drug delivery and has a strong intellectual property position, a portfolio of commercialized OTC drug products, and a pipeline of prescription formulations utilizing its PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that enable the funding of prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and ODTs.

Midatech Group Ltd is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications that have the potential for multiple diagnostic and therapeutic applications.

Created in 2000, Midatech has IP covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas. As well as in-house product development, it is prepared to licence this IP to 3rd Party pharmaceutical and diagnostic development partners whilst retaining manufacturing rights. Midatech has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles. The Company opened a cGMP standard design and manufacturing plant for nanocells -- Midatech Biogune -- in Bilbao, Spain in 2007.

For more information, please click here

Contacts:
MonoSol Rx:
Keith Kendall
Chief Financial Officer
(732) 564-5000
The Ruth Group (on behalf of MonoSol Rx)
Jason Rando (media)
646-536-7025

Stephanie Carrington / Sara Ephraim (investors)
646.536.7017/7002

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Physicists solve quantum tunneling mystery: ANU media release: An international team of scientists studying ultrafast physics have solved a mystery of quantum mechanics, and found that quantum tunneling is an instantaneous process May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

Controlled Release of Anticorrosive Materials in Spot by Nanocarriers May 27th, 2015

Thin films

Sandia researchers first to measure thermoelectric behavior by 'Tinkertoy' materials May 20th, 2015

Defects can 'Hulk-up' materials: Berkeley lab study shows properly managed damage can boost material thermoelectric performances May 20th, 2015

Efficiency record for black silicon solar cells jumps to 22.1 percent: Aalto University's researchers improved their previous record by over 3 absolute percents in cooperation with Universitat Politècnica de Catalunya May 18th, 2015

Science and Technology of Advanced Materials (STAM): Reported successes and failures aid hot pursuit of superconductivity May 15th, 2015

Nanomedicine

New electronic stent could provide feedback and therapy — then dissolve May 27th, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Announcements

Physicists solve quantum tunneling mystery: ANU media release: An international team of scientists studying ultrafast physics have solved a mystery of quantum mechanics, and found that quantum tunneling is an instantaneous process May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

Controlled Release of Anticorrosive Materials in Spot by Nanocarriers May 27th, 2015

Alliances/Partnerships/Distributorships

Samtec, Global Provider of Interconnect Systems, Joins IRT Nanoelec Silicon Photonics Program May 21st, 2015

SUNY Poly CNSE and NIOSH Launch Federal Nano Health and Safety Consortium: May 20th, 2015

Industrial Nanotech, Inc. Announces Official Launch of the Eagle Platinum Tile™ May 19th, 2015

DiATOME enables surface preparation for AFM and FIB May 19th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project